Experience with atezolizumab combination therapy for small cell lung cancer: analysis of the authors’ own data

Gamayunov S.V.

Nizhny Novgorod Regional Clinical Oncology Dispensary

Shegurova M.M.

Nizhny Novgorod Regional Clinical Oncology Dispensary of the Moscow Healthcare Department

Ovchinnikova E.G.

Nizhny Novgorod Regional Clinical Oncology Dispensary of the Moscow Healthcare Department

Shumskaya I.S.

Nizhny Novgorod Regional Clinical Oncology Dispensary of the Moscow Healthcare Department

Kleimentyeva T.P.

Nizhny Novgorod Regional Clinical Oncology Dispensary of the Moscow Healthcare Department

Experience with atezolizumab combination therapy for small cell lung cancer: analysis of the authors’ own data

Authors:

Gamayunov S.V., Shegurova M.M., Ovchinnikova E.G., Shumskaya I.S., Kleimentyeva T.P.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2022;11(3): 36‑40

DOI: 10.17116/onkolog20221103136

Downloaded: 82

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Gamayunov SV, Shegurova MM, Ovchinnikova EG, Shumskaya IS, Kleimentyeva TP. Experience with atezolizumab combination therapy for small cell lung cancer: analysis of the authors’ own data. P.A. Herzen Journal of Oncology. 2022;11(3):36‑40. (In Russ.)
https://doi.org/10.17116/onkolog20221103136

Подписка 2025-2 (P.A. Herzen Journal of Oncology)

Close metadata

OBJECTIVE

To assess data on the efficiency of drug therapy in the clinical practice in the Nizhny Novgorod Regional Clinical Oncology Dispensary (NNRCOD) and to compare those with the results of a registration clinical trial of atezolizumab (IMpower 133) used in the treatment of patients with advanced stages of small cell lung cancer.

Subjects and methods. A follow-up group included 33 patients who received combination chemotherapy regimen: atezolizumab 1200 mg on day 1 + etoposide 100 mg/m² on days 1—3 + carboplatin AUC5 on day 1 (a 21-day cycle), 4 cycles; in disease stabilization, treatment was continued as maintenance monoimmunotherapy cycles according to the regimen: atezolizumab 1200 mg on day 1 (a 21-day cycle) until disease progression or during unacceptable toxicity.

RESULTS

The analysis showed that the median progression-free survival was 5.2 and 6 months in IMpower 133 trial and NNRCOD, respectively. The two-year median overall survival (OS) in our clinic was 29.5 months; 22.9-month OS during the IMpower 133 trial was 12.3 months.

CONCLUSION

The results of using a combination of these drugs have proven their clinical efficiency and satisfactory safety in daily clinical practice.

Keywords:

small cell lung cancer

immunotherapy

atezolizumab

Authors:

Gamayunov S.V.

Nizhny Novgorod Regional Clinical Oncology Dispensary

Shegurova M.M.

Nizhny Novgorod Regional Clinical Oncology Dispensary of the Moscow Healthcare Department

Ovchinnikova E.G.

Nizhny Novgorod Regional Clinical Oncology Dispensary of the Moscow Healthcare Department

Shumskaya I.S.

Nizhny Novgorod Regional Clinical Oncology Dispensary of the Moscow Healthcare Department

Kleimentyeva T.P.

Nizhny Novgorod Regional Clinical Oncology Dispensary of the Moscow Healthcare Department

Received:

16.05.2022

Accepted:

24.05.2022

List of references:

Kaprin AD, Starinskij VV, Shakhzadova AO, eds. Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2020. M.: MNIOI im. P.A. Gertsena — filial FGBU «NMITS radiologii» Ministerstva zdravookhraneniya Rossijskoj Federatsii; 2020. (In Russ.).
Hurwitz JL, McCoy F, Scullin P & Fennell DA. Second-Line Treatment of Small Cell. Oncologist. 2009;14(10):986-994. https://doi.org/10.1634/theoncologist.2009-0026
Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now? A review. Transl Lung Cancer Res. 2016;5(1):26-38. https://doi.org/10.3978/j.issn.2218-6751.2016.01.13
Lampaki S, Zarogoulidis P, Lagoudi K, et al. Small Cell Lung Cancer: Current and Future Strategies. Oncomedicine. 2016;1:4-13. https://doi.org/10.7150/oncm.16926
Horn L, Mansfeld AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229. https://doi.org/10.1056/NEJMoa1809064
Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-421. https://doi.org/10.1038/nature12477
Khanna P, Blais N, Gaudreau P-O, Corrales-Rodriguez L. Immunotherapy Comes of Age in Lung Cancer. Clin Lung Cancer. 2017;18(1):13-22. https://doi.org/10.1016/j.cllc.2016.06.006.
Hellmann MD, Callahan MK, Awad MM, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018;33(5):853-861.e4. https://doi.org/10.1016/j.ccell.2018.04.001
Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase II study of maintenance pembrolizumab in patients with extensivestage small cell lung cancer (SCLC). J Thorac Oncol. 2018;13:1393-1399. https://doi.org/10.1016/j.jtho.2018.05.002.
Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34:3740-3748. https://doi.org/10.1200/JCO.2016.67.6601
Kuz’minov AE, Laktionov KK, Egorova AV, et al. Immunoterapiia melkokletochnogo raka legkogo. Meditsinskii sovet. 2019;10:22-27. (In Russ.). https://doi.org/10.21518/2079-701X-2019-10-22-27.
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-1939. https://doi.org/10.1016/S0140-6736(19)32222-6

Close metadata